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Abstract: Angiogenesis drives evolution and destabilisation of atherosclerotic plaques and the growth
and expansion of tumour cells. Vascular endothelial growth factor (VEGF) is the main endogenous
pro-angiogenic factor in humans. The aim was to provide insight into the anti-VEGF activity
of bioactive compounds derived from aromatic amino acids (serotonin, melatonin, 3-indoleacetic
acid, 5-hydroxytryptophol and hydroxytyrosol). Experiments involved endothelial cell migration
(wound-healing assay), the molecular mechanisms (ELISA assay) and the downstream effects
(phospholipase C gamma 1 (PLCγ1), protein kinase B (Akt) and endothelial nitric oxide synthase
(eNOS) by Western blot) on human umbilical vein endothelial cells (HUVECs). The data suggest
for the first time that hydroxytyrosol interacts with surface components of the endothelial cell
membrane (, preventing VEGF from activating its receptor. Serotonin and 5-hydroxytryptophol
significantly inhibited HUVEC migration (98% and 50%, respectively) following the same mechanism.
Conversely to other bioactive compounds, the anti-angiogenic effect of melatonin, serotonin,
3-indoleacetic acid and 5-hydroxytryptophol is not mediated via PLCγ1. However, hydroxytyrosol
inhibits PLCγ1 phosphorylation. Additionally, melatonin and serotonin maintained eNOS
phosphorylation and hydroxytyrosol significantly activated eNOS—all via Akt. These data provide
new evidence supporting the interest in melatonin, serotonin, 3-indoleacetic acid, 5-hydroxytryptophol
and hydroxytyrosol for their further exploitation as anti-VEGF ingredients in food.
Keywords: VEGF; angiogenesis; melatonin; serotonin; 3-indoleacetic acid; 5-hydroxytryptophol;
hydroxytyrosol; PLCγ1; Akt; eNOS
1. Introduction
Worldwide, cardiovascular diseases and cancer are the two main causes of death (31% and 16% of
deaths in 2015, respectively) [1,2]. Both diseases share the critical component of forming new blood
vessels (angiogenesis), driving both the growth and advance of tumour cells and the evolution and
destabilisation of atherosclerotic plaques [3,4]. Moreover, vascular endothelial growth factor (VEGF),
which is the main endogenous pro-angiogenic factor in humans [5–8], has been demonstrated to
promote atherosclerotic plaque progression [3,9] and tumoral angiogenesis [10]. Vascular endothelial
growth factor works by stimulating its principal receptor VEGFR-2, the latter being crucial for
promoting endothelial cell proliferation, differentiation and migration [5,11]. Since VEGF is the
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main pro-angiogenic factor, VEGF signalling inhibition is a plausible molecular mechanism which
demonstrates a direct cause–effect relationship in reducing the risk of cardiovascular disease and cancer.
Proof of the crucial function of VEGF in angiogenesis is the fact that certain drugs currently used
to treat cancer, such as bevacizumab—the most widely used at present in treating breast, lung, kidney,
liver and colon cancer—consist of anti-VEGF molecule treatment [12,13]. Nevertheless, their long-term
use has been associated with serious adverse effects such as hypertension [14,15] due to the fact that
VEGF inhibition also drives the inhibition of intracellular proteins such as endothelial nitric oxide
synthase (eNOS), responsible for generating nitric oxide which is involved in vasodilation.
Certain bioactive compounds present in the Mediterranean diet, such as polyphenols and indolic
compounds, have been demonstrated to inhibit VEGF signalling [16–20]. Hence, polyphenols such as
epigallocatechin gallate (EGCG), procyanidin tetramers (dp4), quercetin, etc., present in apples, green
tea, onions, or cocoa, have been demonstrated to interact directly with the VEGF molecule, rendering
it completely inactive [16,17]. Likewise, Moyle et al. [16] proved that not only did EGCG and dp4
procyanidins inhibit VEGF but they also simultaneously increased eNOS phosphorylation in human
umbilical vein endothelial cells (HUVECs), something which would, presumably, increase vasodilation.
Our research group has recently shown that certain stilbene compounds present in grapes and wine,
such as astringin, pallidol, ω-viniferin and ε-viniferin, also have a potential anti-VEGF effect, with
only ε-viniferin and pallidol allowing eNOS phosphorylation [20]. Therefore, these data support
that not all bioactive compounds which inhibit VEGF have the ability to simultaneously stimulate
eNOS. Hydroxytyrosol, present in olive oil and wine [21,22], has also been shown to potentially inhibit
VEGF signalling and HUVEC migration [18]. However, its molecular mechanism and effect on eNOS
modulation have not been explored, which is an important factor, as it is a European Food Safety
Authority (EFSA) requirement for supporting food bioactive health claims.
Our research group has also recently demonstrated that melatonin, present in an extensive array of
foods, such as vegetables and their fruits and seeds, medicinal herbs, and fermented products (tomatoes,
pistachio, strawberry, cherry, bread, olive oil, wine, beer, etc.), as well as other bioactive indolic
compounds (e.g., serotonin, 3-indolacetic acid), also present in fermented food (wine and beer) [23–30],
and one of the serotonin human metabolites (5-hydroxytryptophol) [31,32] possess potential anti-VEGF
signalling effects [19]. This research has demonstrated that these indolic compounds present a different
anti-VEGF molecular signalling mechanism to that of phenolic compounds; serotonin, 3-indolacetic
acid, melatonin and 5-hydroxytryptophol appear to interact with the cell surface components of the
endothelial membrane, such as VEGFR-2, among others, preventing VEGF from activating the receptor.
Therefore, these data reveal that not all bioactive compounds possess the same anti-VEGF molecular
signalling mechanism of action. This work has also proved that melatonin and 3-indolacetic acid
inhibit HUVEC migration, demonstrating its anti-angiogenic effect. However, the effect of serotonin
and 5-hydroxytryptophol on inhibiting HUVEC migration, and the influence of 3-indolacetic acid,
melatonin, 5-hydroxytryptophol and serotonin on modulating the intracellular pathways are both
still unexplored.
The aim of the present study was to: (i) provide insight into hydroxytyrosol’s possible
anti-angiogenic mechanism of action, (ii) evaluate the anti-angiogenic effect of serotonin and
5-hydroxytryptophol on HUVECs, and (iii) determine the downstream effects (phospholipase C gamma
1 (PLCγ1), protein kinase B (Akt) and eNOS) of bioactive compounds (serotonin, 5-hydroxytryptophol,
3-indolacetic acid, melatonin and hydroxytyrosol) which induce VEGF signalling inhibition. Since these
bioactive compounds are present concurrently in the diet, this work aims to evaluate their cocktail
effect upon the inhibition of VEGF-induced VEGFR-2 activation.
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2. Materials and Methods
2.1. Cell Culture
The HUVECs (Lonza, Slough, UK) between passages 4 and 5 were kept in endothelial growth
medium-2 (EGM-2) (Lonza, Slough, UK) at 37 ◦C and 5% CO2.
2.2. Compounds Under Study
Serotonin, melatonin and 3-indolacetic acid were obtained from Sigma–Aldrich (St. Louis, MO,
USA). 5-Hydroxytryptophol and hydroxytyrosol were acquired from Cayman Chemical (Ann Arbor,
MI, USA).
2.3. Treatment of HUVECs
The HUVECs were grown to confluence and exposed to endothelial basal medium (EBM)
containing either the individual compounds under study (indolic compounds at 1 mM and
hydroxytyrosol at 1 and 50 µM; final concentration of ≤0.1% dimethyl sulfoxide (DMSO)) or
DMSO for vehicle controls (≤0.1% DMSO). These compound concentrations were according to
the previous anti-VEGF effect reported in the literature [18,19]. The cells were then incubated
for 4 h at 37 ◦C. Stimulation with VEGF (25 ng/mL) (VEGF165, R&D Systems, Minneapolis, MN,
USA) was then conducted for 5, 10 or 60 min depending on whether VEGFR-2, PLCγ1 or Akt
and eNOS phosphorylation, respectively, was being determined. Each sample was analysed in
duplicate, and experiments were performed twice. After the treatments, cells were lysed by
radioimmunoprecipitation and total protein content quantified by bicinchoninic acid (BCA) assay.
In the case of hydroxytyrosol, three different experimental conditions (previously designed in
Moyle et al. [16]) were tested in order to elucidate the molecular mechanism for inhibiting VEGF-induced
VEGFR-2 phosphorylation: (1) a mixture of hydroxytyrosol and VEGF 5 min prior to cell treatment with
the mixture for other 5 min; (2) cell pre-incubation with hydroxytyrosol for 4 h prior to cell incubation
with VEGF for 5 min; and (3) cell pre-treatment with hydroxytyrosol for 4 h, washing passage and
stimulation with VEGF for 5 min. Finally, in order to determine the hydroxytyrosol IC50 value,
experiments were carried out testing six different concentrations (1–100 µM) after 4 h of pre-incubation
(experimental design 2).
2.4. VEGFR-2 Phosphorylation (ELISA Assay)
The PathScan Phospho-VEGFR-2 (Tyr 1175) sandwich ELISA kit (Cell Signaling Technology,
Hitchin, UK) was used to quantify VEGFR-2 activation in protein lysates, the procedure being
performed following the manufacturer’s instructions.
2.5. Determination of PLCγ1, Akt and eNOS Modulation by Western Blot
Denaturalised protein lysates (25 µg) (with lithium dodecyl sulphate and DTT at 70 ◦C for
10 min) (Invitrogen, Loughborough, UK) were loaded on NuPAGE 4%–12% Bis-Tris (Invitrogen,
Loughborough, UK) gels and separated by electrophoresis. Subsequently, proteins were transferred
to 0.2 µm nitrocellulose membranes (Bio-Rad, Hercules, CA, USA) and incubated with anti-phospho
antibodies and total proteins of PLCγ1 (Tyr 783; Ref 2821 and 5690), Akt (Ser 473; Ref 4060 and
9272) and eNOS (Ser 1177; Ref 9570 and 9572) (Cell Signaling Technology). The membranes were
visualised using secondary anti-rabbit antibodies IgG-HRP (Ref 7074) and SuperSignal West Pico
chemiluminescent substrate (Thermo Scientific, Hitchin, UK) on an Amersham Imager 600 station (GE
Healthcare live sciences, Marlborough, MA, USA).
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2.6. Evaluation of Migration (Wound-Healing Assay)
The cell migration assay was performed following the protocol previously described in Cerezo
et al. [19]. The HUVECs were placed onto 50 mm imaging dishes (Ibidi, Martinsried, Germany).
Once cells reached full confluence, the monolayer was scratched across the centre using a sterile
200 µL pipette tip. Subsequently, the cells were then rinsed twice with PBS to eliminate any dead
cells. Serum-free medium containing 1 mM serotonin, 1 mM 5-hydroxytryptophol or vehicle controls
were added (final concentration ≤ 0.1% DMSO) for 4 h prior to VEGF stimulation (25 ng/mL) over
24 h. A phase contrast microscope (Nikon, Tokyo, Japan) was used to photograph the wound-gaps.
Nis-Elements BR v.4.30.02 software (Nikon, Tokyo, Japan) was utilised to measure the initial and final
sizes of each wound. The following formula was used to quantify the migration distance: initial wound
size minus final wound size divided by two. Two independent experiments were performed.
2.7. Statistical Analysis
Significant differences among samples were analysed using Student’s t-test in GraphPad Prism
software version 6.01 (GraphPad Software, Inc., San Diego, CA, USA).
3. Results
3.1. Hydroxytyrosol in the Inhibition of Angiogenesis: Molecular Mechanism
To elucidate hydroxytyrosol’s molecular mechanism, three different experiments were performed
(Figure 1). First, either vehicle control or hydroxytyrosol (1 µM and 50 µM) with VEGF (25 ng/mL)
were mixed for 5 min prior to treating HUVECs for 5 min. The results in this paper show that the
hydroxytyrosol treatment failed to inhibit VEGF-induced VEGFR-2 phosphorylation (Figure 1A). Thus,
these results rejected the hypothesis that, like other phenolic compounds such as epigallocatechin
gallate or quercetin, among others [16], hydroxytyrosol could interact directly with the VEGF protein.
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Figure 1. Hydroxytyrosol inhibits vascular endothelial growth factor (VEGF)-induced VEGFR-2
phosphorylation by interacting with cell membrane components. Human umbilical vein endothelial
cells (HUVECs) were incubated with 50 µM or 1 µM hydroxytyrosol and VEGF (25 ng/mL).
(A) Hydroxytyrosol and VEGF were mixed 5 min prior to cells treatment for another 5 min;
(B) hydrox tyr sol was pre-incubated for 4 h with HUVECs and subsequently incubated with
VEGF for 5 min; (C) hydroxytyrosol was pre-incubated for 4 h with HUVECs and, after removal of
the polyphenol (with PBS), was then stimul te with VEGF for 5 min. p-VEGFR-2 (Tyr1175) was
quantified by ELISA essay; * p < 0.1, **** p < 0.0001 in comparison to the stimulated cells with VEGF
alone. Data are expressed as the mean ± SD (n = 4). OH-Tyrosol: hydroxytyrosol.
Secondly, HUVECs were incubated with either vehicle control (≤0.1% DMSO) or hydroxytyrosol
(1 µM and 50 µM) for 4 h before stimulating them with VEGF (25 ng/mL) for 5 min. Hydroxytyrosol at
50 µM significantly inhibited VEGFR-2 phosphorylation by 37% compared to control with VEGF only
(Figure 1B). These results support the notion t at hydroxytyrosol could bind to VEGFR-2 or any of its
c -receptors such as heparan ulphate prote glycans (HSPGs) or neuropilins (NRPs), affecting the
activati n of VEGFR-2.
Thirdly, HU Cs were incubated with 50 µM hydroxytyrosol (active concentration) for 4 h.
The cells were then washed twi e with PBS and stimulated with new media containing VEGF only
(25 ng/mL) for 5 min. The results proved that hydroxytyrosol still significantly i hibited VEGFR-
activation by 23% (Figure 1C). The s cond and third experimental designs led us to hypotheses
tha hydroxytyrosol co ld interact both with VEGFR-2 or any of its co-receptors at the extracellular
domain. This is probably due to a non-strong binding, which can be moved in the rinsing step,
and, in addition, can interact with any sub-cellular kinase, w i h could explain the remai ing 23% of
pVEGFR-2 inhibition.
Figure 1B shows that hydroxytyrosol inhibition of VEGF-induced VEGFR-2 phosphorylation
appeared to occur in a concentration-dependent manner, which agrees with Lamy et al. [18]. Therefore,
the half maximal inhibition (IC50) of hydroxytyrosol under the abovementioned 4 h pre-incubation
conditions was t en deter ined, giv ng the result that IC50 = 72.4 µM (Table 1).
Table 1. Vascular endothelial growth factor (VEGF)-induced VEGFR-2 inhibition percentage (%) of
individual and combined compounds.
Compounds Concentration
(mM)
VEGFR-2
Inhibition %
(Individual
Compounds)
Reference
VEGFR-2 Inhibition % (Combined Compounds)
3-Indole
Acetic Acid Serotonin Melatonin 5-Hydroxytryptophol
3-Indole acetic acid 1 53.56 ± 1.39IC50 = 970.4 µM
[19]
— 36.42 ± 10.31 38.86 ± 6.90 8.89 ± 9.46
Serotonin 1 29.56 ± 14.36 — 43.84 ± 9.21 8.89 ± 9.46
Melatonin 1 32.15 ± 1.87 — NI
5- Hydroxytryptophol 1 22.99 ± 7.02 —
Hydroxytyrosol 0.05
36.69 ± 6.13
IC50 = 72.40 µM
(60.32–86.90)
Figure 1B 59.10 ± 8.26 31.03 ± 14.26 48.89 ± 5.61 * 28.26 ± 0.0
Inhibition percentages of VEGFR-2 activation are expressed as the mean ± SD (n = 4). * p < 0.05 versus individual
compounds. The 95% confident intervals of the IC50 values are shown in parenthesis. NI: non-inhibition.
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3.2. Anti-Angiogenic Effect of Serotonin and 5-Hydroxytryptophol: Inhibition of HUVEC Cell Migration
Since serotonin and 5-hydroxytryptophol have been demonstrated to inhibit VEGFR-2
phosphorylation in previous studies [19], their anti-angiogenic effect on HUVEC migration was
evaluated by performing wound healing essays. Endothelial cells that were stimulated with VEGF
for 24 h refilled the wound closure (Figure 2), whereas cells pre-treated with either serotonin or
5-hydroxytryptophol reduced cell migration by 97% and 50%, respectively, after 24 h (Figure 2).
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Figure 2. Serotonin and 5-hydroxytryptophol inhibited HUVEC migration. HUVECs were placed onto
50 mm imaging dishes and wounded. Then, they were incubated with 1 mM of 5-hydroxytryptophol
and serotonin for 4 h and subsequently stimulated with VEGF. Representative photomicrographs were
taken at 0 h and 24 h of VEGF stimulation. Scale bars: 200 µm.
3.3. Downstream Effects of Melatonin, Serotonin, 3-Indolacetic Acid, 5-Hydroxytryptophol and Hydroxytyrosol
on PLCγ1, Akt and eNOS Activation
Vascular endothelial growth factor is known to mediate different events in angiogenesis
through a complex intracellular signalling cascade [33]. Since 3-indolacetic acid, melatonin,
5-hydroxytryptophol, serotonin and hydroxytyrosol have been demonstrated to inhibit VEGF-induced
VEGFR-2 phosphorylation [19] (Figure 1) and cell migration [18,19] (Figure 2), determining which
downstream substrates could be implicated in the inhibitory activity of the compounds under study is
of great interest. First, we evaluated whether the anti-angiogenic properties of melatonin, serotonin,
3-indolacetic acid, 5-hydroxytryptophol and hydroxytyrosol was mediated by the inhibition of PLCγ1,
the main protein involved in the cell proliferation. The results showed that after VEGF stimulation,
PLCγ1 became phosphorylated, but pre-incubating the cells with the indolic compounds caused no
significant differences in the pPLCγ1/PLCγ1 ratio compared to the positive control with only VEGF
(Figure 3A–C). For this reason, the present data support that these compounds’ inhibitory effects on
angiogenesis are not mediated by PLCγ1 inhibition. Interestingly, hydroxytyrosol proved to inhibit
PLCγ1 phosphorylation (41% inhibition) (Figure 3D,E) which, until then, had not been referenced.
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Figure 3. Hydroxytyrosol inhibits PLCγ-1 phosphorylation. HUVECs were treated with (A–C)
3-indolacetic acid (1 mM), 5-hydroxytryptophol (1 mM), melatonin (1 mM) and serotonin (1 mM),
and (D and E) hydroxytyrosol (50 µM) for 4 h and then incubated with VEGF (25 ng/mL) for 10
min. Western blot membranes were incubated with anti-PLCγ-1 and anti-p-PLCγ-1 antibodies. Data
representations of the p-PLCγ-1/PLCγ-1 ratio are expressed as the mean ± SD (n = 4). * p <0.05;
** p < 0.01; *** p < 0.001 versus VEGF alone. IAA: 3-indolacetic acid; 5-HTOL: 5-hydroxytryptophol;
Mel: melatonin; Ser: serotonin.
Secondly, the effect of these compounds on Akt and eNOS activation, which are proteins activated
later in the VEGF signalling cascade, was evaluated. In particular, eNOS modulates the nitric oxide
generation (NO) via Akt phosphorylation [34,35]. The results obtained in this work demonstrate
that VEGF alone activates Akt and eNOS phosphorylation (Figure 4). Additionally, melatonin and
serotonin treatment significantly enhanced VEGF-induced Akt phosphorylation and maintained the
peNOS/eNOS ratio in the presence of VEGF (Figure 4A, and Table 2). In contrast, 3-indole acetic acid
and 5-hydroxytryptophol inhibited VEGF-induced Akt and eNOS phosphorylation (Figure 4B–D).
This work’s results also showed that hydroxytyrosol significantly increased both Akt and eNOS
phosphorylation (Figure 4E,F).
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phosphorylation; hydroxytyrosol significantly increased pAkt/Akt and peNOS/eNOS ratios. HUVECs
were treated with (A) melatonin (1 mM) and serotonin (1 mM); (B–D) 3-indolacetic acid (1 mM) and
5-hydroxytryptophol (1 mM); and (E and F) hydroxytyrosol (50 µM) for 4 h and then incubated with
VEGF (25 ng/mL) for 60 min. Western blot membranes were incubated with anti-Akt and anti-p-Akt
antibodies and anti-eNOS and anti-p-eNOS antibodies. Data representations of the p-Akt/Akt and
peNOS/eNOS ratios are expressed as the mean ± SD (n = 4). * p <0.05; ** p < 0.01 versus negative
control. IAA: 3-indolacetic acid; 5-HTOL: 5-hydroxytryptophol; Mel: melatonin; Ser: serotonin.
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Table 2. Ratio peNOS/ endothelial nitric oxide synthase (eNOS) values for melatonin and serotonin.
Ratio peNOS/eNOS Values
Negative 1.35 ± 1.47
VEGF 1.23 ± 0.78
Melatonin 1.05 ± 0.72
Melatonin + VEGF 1.51 ± 0.92
Serotonin 1.57 ± 0.76
Serotonin + VEGF 2.25 ± 1.06
Experimental conditions are described in Figure 4.
3.4. Effects of Combined Compounds on the Inhibition of VEGF-Induced VEGFR2 Activation
The human diet consists of a great variety of foods, including ones that are sources of these bioactive
compounds under study. The cocktail effect of 3-indolacetic acid, melatonin, 5-hydroxytryptophol,
serotonin and hydroxytyrosol on the anti-VEGF effect by determining the inhibition of VEGFR-2
phosphorylation was, therefore, evaluated. The results showed that the combination of the indolic
compounds did not improve the inhibition percentage of VEGFR-2 phosphorylation (Table 1). However,
the combination of melatonin and hydroxytyrosol significantly improved the inhibition percentage of
VEGFR-2 phosphorylation compared with both compounds alone (Table 1).
4. Discussion
A number of polyphenol compounds usually synthesised in plant foods, such as EGCG, quercetin
or dp4 procyanidins, have been shown to directly inhibit the VEGF molecule as an anti-angiogenic
molecular mechanism [16]. Hydroxytyrosol has also previously been demonstrated to also inhibit
VEGF-induced VEGFR-2 activation, cell proliferation, cell migration and tubular formation in
HUVECs [18]. However, both its molecular target and its underlying molecular mechanism are still
unknown. In this study, data are presented for the first time supporting that extra- and intra-cellular
interactions between hydroxytyrosol and components of the cell surface (VEGFR-2, neurophilins, etc.)
could be proposed as a molecular mechanism to explain its anti-angiogenic effect (Figure 1). Therefore,
despite hydroxytyrosol being a polyphenol compound, it does not share the same anti-angiogenic
molecular mechanism of directly binding to VEGF; rather, it interacts with cell membrane constituents
and prevents VEGF from activating its receptor VEGFR-2 in a similar manner to serotonin, 3-indolacetic
acid, melatonin and 5-hydroxytryptophol [19].
Lamy et al. [18] determined that pre-stimulating cells with hydroxytyrosol for 24 h inhibited
the phosphorylation of VEGFR-2 in Tyr1175 residue with an IC50 of 30 µM. Since the half-life of
hydroxytyrosol in plasma is 2.43 h [36], the results obtained in this work—pre-stimulating for 4 h
only—are more likely to occur in vivo. Thus, IC50 was calculated under the 4 h pre-stimulation
conditions and resulted at a concentration of 72.4 µM. When compared to the indolic compounds
under study (Table 1) which share a similar molecular mechanism, hydroxytyrosol exhibits the
highest anti-angiogenic potential, achieving similar pVEGFR-2 inhibition values at concentrations 1000
times smaller.
Interestingly, endothelial cell migration is essential for the initial state of angiogenesis [37].
Therefore, this paper describes for the first time that both serotonin and 5-hydroxytryptophol are
potent anti-angiogenic molecules (97% and 50% of migration inhibition, respectively, at 1 mM; Figure 2).
This research group has previously demonstrated that melatonin and 3-indolacetic acid, under the
same conditions (4 h pre-incubation treatment and at 1 mM), also possess a potent anti-migratory effect
on HUVECs [19]. Therefore, the indolic anti-migratory effect, based on their cell migration inhibition
percentages, could be ranked as follows: 3-indolacetic acid (99%) [19] > serotonin (97%) (Figure 2) >
melatonin (87%) [19] > 5-hydroxytryptophol (50%) (Figure 2). Considering the inhibition percentage
of VEGFR-2 phosphorylation of the different indolic compounds under study (3-indolacetic acid (54%)
> serotonin (32%) > melatonin (30%) > 5-hydroxytryptophol (23%)) [19] and the ranking of their
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anti-migratory effect, it was observed that they present an identical compound order. However, the
migration values were observed to be higher than the inhibition percentage of pVEGFR-2 in all cases,
suggesting that the inhibition of VEGFR-2 phosphorylation is not the only mechanism underlying their
anti-angiogenic activity. Indeed, other authors have demonstrated that melatonin inhibits angiogenesis
by modifying the expression of intracellular proteins, such as p53 and Bax/Bcl-2, blocking the cellular
cycle, inducing apoptosis [38] and reducing cellular proliferation through intracellular proteins (ERK1/2,
PI3k, Akt, PKC, NF-kB) mediated by melatonin receptors MT1 and MT2 [39]. Similarly, 3-indolacetic
acid, serotonin and 5-hydroxytryptophol could also be modulating these or similar proteins while
inhibiting cell migration. Moreover, the effect of hydroxytyrosol on HUVEC migration has been
previously described, showing a 59% inhibition rate, although the concentration tested (50 µM)
was lower.
Vascular endothelial growth factor-induced VEGFR-2 activation initiates a complex intracellular
regulation cascade involving a large number of endogen molecule angiogenic signalling transduction.
The biological role of PLCγ1, the first component of the principal VEGFR-2 pathway, has been
described in modulating both migration and cell proliferation [40–42]. For this reason, this work
evaluated whether the inhibition of cell migration in the presence of 3-indolacetic acid, melatonin,
5-hydroxytryptophol, serotonin and hydroxytyrosol was somehow mediated by PLCγ1 inhibition,
as has been demonstrated for other bioactive compounds such as epigallocatechin gallate and
procyanidin tetramers [16]. The present data (Figure 3A) suggest that all of the compounds tested
except hydroxytyrosol failed to deactivate PLCγ1. The results, therefore, demonstrate for the first time
that hydroxytyrosol’s anti-angiogenic effect is mediated by the inhibition of PLCγ1 phosphorylation.
In fact, its VEGFR-2 phosphorylation inhibition percentage (36.69% of inhibition) (Table 1) and PLC
γ1 (41% of inhibition) (Figure 3B) are quite similar. For the indolic compounds, three pathways
might be involved: Shb-Sck-PI9K-Rac-IQGAPI, p38/MAPK-HSP27 and TSAd/Src, all of which are also
related to cell migration [33]. Since all of the compounds studied have demonstrated their ability to
inhibit VEGFR-2 phosphorylation on the Tyr1175 residue [19], the most probable pathway would be
Shb-Sck-PI9K-Rac-IQGAPI, mediated by the abovementioned tyrosine residue. Nevertheless, future
works would need to be conducted in order to confirm the correct molecular pathway.
Vasodilation is also a VEGF-regulated function through VEGFR-2 activation. This activates eNOS,
via Akt, stimulating the formation of NO [34,35]. Certain anti-VEGF drugs, such as bevacizumab,
sorafenib and sunitinib, currently employed in cancer therapies, have been shown to increase patients’
risk of suffering hypertension, as a consequence of their VEGF inhibiting effect [14,15,43,44]. However,
a number of bioactive compounds such as EGCG and procyanidin tetramers have been demonstrated to
not only inhibit VEGF, but also concurrently activate eNOS via Akt [16]. This present study has proved
that melatonin and serotonin are able to maintain eNOS phosphorylation (Table 2); hydroxytyrosol
significantly activating eNOS (Figure 4F), all three via Akt activation. It may be expected, therefore,
that these compounds induce NO bioavailability avoiding the adverse hypertensive effects associated
with VEGF inhibitors. To reinforce the results presented here, further research would be necessary in
order to evaluate the in vivo effect of these compounds on NO bioavailability.
In the case of VEGF-induced VEGFR-2 phosphorylation, this is the first time that the combination
of melatonin and hydroxytyrosol has proved to be more effective in inhibiting VEGF-induced VEGFR-2
activation than using them separately (Table 1). Since melatonin and hydroxytyrosol, when used
separately, were also able to maintain and increase, respectively, eNOS phosphorylation, other studies
should be performed to evaluate the effect of their combination on eNOS activation.
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